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Abstract
OBJECTIVE: Paraquat (PQ) poisoning-induced pul-
monary fibrosis causes asphyxiation and death. The
therapeutic potential of intravenous Xuebijing ther-
apy in PQ poisoning patients and its underlying im-
munomodulatory effects on transforming growth
factor (TGF)-β1 and procollagen type III peptide
(PIIIP) were investigated.
METHODS: Thirty-six acute PQ poisoning patients
were randomly assigned to conventional therapy
(Group A) and intravenous Xuebijing administra-
tion plus conventional therapy (Group B). Twenty
volunteers served as controls (Group C). Blood sam-
ples were collected upon admission (day 0) and at
post-treatment days 5, 10, and 14. TGF-β1 and PIIIP
concentrations were determined by ELISA and ana-
lyzed for intra- and inter-group differences over
time. One-month follow-up was conducted for de-
termining the mortality rate.
RESULTS: TGF-β1 and PIIIP levels were significantly
higher in PQ poisoning patients and increased over
time (Groups A and B vs C, P<0.01). However, the
TGF-β1 and PIIIP levels were consistently significant-
ly lower in Group B compared with those of Group
A (P<0.01). The 1-month mortality rate was also
lower in Group B compared with that of Group A
(P<0.05). PQ poisoning patients showed remark-
ably high levels of TGF-β1 and PIIIP, which increased
as PQ-induced pulmonary fibrosis progressed.
CONCLUSION: Treatment with intravenous Xuebi-
jing plus conventional therapy significantly low-
ered TGF-β1 and PIIIP levels, which indicates thera-
peutic efficacy in the treatment of PQ poisoning pa-
tients.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Paraquat (PQ) is one of the most commonly used her-
bicides worldwide. PQ is highly toxic to humans, and
skin contact (long-term) or oral ingestion is associated
with a high mortality rate. Ingestion of >20 mL of a 20%
PQ preparation causes rapid death within 1-4 days from
a systemic inflammatory response that leads to
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multi-organ failure and cardiogenic shock. Ingestion of
smaller quantities, between 10-20 mL, also leads to
death, but the process is slower. The process takes sever-
al weeks and occurs by excessive and irreversible lung fi-
brosis and renal failure.1 The molecular mechanisms
underlying PQ-induced pulmonary fibrosis and multi-
organ failure have yet to be fully elucidated. Immuno-
modulatory molecules, such as cytokines and oxygen
free radicals, are considered likely functional contribu-
tors to the PQ pathogenic process.
Xuebijing is a plant-derived Traditional Chinese Medi-
cine that has been successfully applied to treat inflam-
mation-associated diseases, such as sepsis and severe
pneumonia.2 Although the major constituents of the
Xuebijing medicinal preparation have only recently
been identified, the mechanism of its action is largely
unknown.3 Some studies have revealed specific effects
on various immunomodulatory factors and processes.
Xuebijing treatment of peripheral blood mononuclear
cells stimulated by exposure to purified bacterial endo-
toxin lipopolysaccharide (LPS) led to decreases in tis-
sue factor (TF) and protease-activated receptor (PAR)
expression.4 Severe pneumonia patients treated with
Xuebijing showed decreased secretion of tumor necro-
sis factor-alpha (TNF-α) and interleukin (IL)-6 and
IL-8, as did patients with sepsis.5 In an intestinal isch-
emia-reperfusion rat model, treatment with intrave-
nous Xuebijing also demonstrated a protective effect
against gut immunologic barrier dysfunction.6 Because
PQ poisoning principally involves systemic inflamma-
tion and excessive immune response (fibrosis), treat-
ment with intravenous Xuebijing therapy holds prom-
ise for the treatment of inflammation-associated diseas-
es, and may prove useful as an experimental tool to
identify the immune factors involved in PQ-induced
complications that lead to severe illness and death.7
In this study, intravenous Xuebijing therapy plus con-
ventional treatment was administered to PQ poisoning
patients and assessed for its efficacy compared with
conventional treatment alone. The effects of the intra-
venous Xuebijing therapy on particular cytokines,
transforming growth factor-β1 (TGF-β1) and type III
procollagen peptide (PIIIP), were also investigated to
help determine what immune factors and pathways
were critically involved in PQ pathogenesis and targets
of Xuebijing.
METHODS
The study was approved by the Ethics Committee of
China-Japan Union Hospital. Informed consent was
obtained from all participants.
Patients
Thirty-six consecutive patients who presented to the
Department of Emergency Medicine at the China-Ja-
pan Union Hospital from February 2007 to February
2009 with acute PQ poisoning were enrolled in the
study. Participants were randomly assigned to receive ei-
ther conventional therapy (Group A, n=19) or intrave-
nous Xuebijing-supplemented therapy (Group B, n=17).
Twenty outpatients were recruited from the outpatient
department to serve as controls (Group C). No statisti-
cally significant differences in gender ratio (male:fe-
male) or age among the three groups were observed. In
addition, there were no statistically significant differ-
ences among the two PQ experimental groups in the
dose of PQ ingested and the time elapsed from suffer-
ing the poisoning to initiation of clinical intervention
(gastric lavage) (all P>0.05) (Table 1).
Treatment protocol and data collection
All PQ poisoning patients first received gastric lavage
(21 patients at local hospitals prior to admission and
15 patients at our hospital immediately upon admis-
sion). Subsequently, catharsis was performed with man-
nitol or magnesium sulfate to scavenge residual PQ
from the gastrointestinal tract, and two or three rounds
of hemoperfusion were performed to eliminate the PQ
that was absorbed into blood. Conventional medica-
tions that were administered to all PQ poisoning pa-
tients included methylprednisolone, vitamin C, vita-
min E, and acetylcysteine (effervescent tablet). For pa-
tients who ingested PQ doses >20 mL, 40 mg of pred-
nisone (in tablet form) was given daily for 1 month.
Other treatments included the administration of pro-
ton pump inhibitors to prevent gastrointestinal tract
mucous membrane injury and mouthwash with metro-
nidazole to prevent mouth mucosa ulcers. Low FiO2
mechanical ventilation was used only in patients who
developed severe hypoxemia (PaO2 <40 mmHg). For
patients in Group B, all of the steps and methods of
the conventional treatment were given, but intrave-
nous Xuebijing therapy (manufactured by Tianjin
Table 1 Clinical patient data among different groups ( xˉ ±s)
Group
A
B
C
n
19
17
20
Gender
M
7
6
10
F
12
11
10
Age (year)
39.5±12.6
37.3±12.2
41.2±13.3
Dose of PQ ingested (mL)
29.2±10.4
31.7±12.6
－
Time elapsed from morbidity
to gastric lavage (h)
3.1±0.6
3.2±0.7
－
Time elapsed from morbidity
to medication (h)
4.3±1.2
4.6±1.1
－
Notes: A: patients treated with conventional therapy; B: patients treated with intravenous Xuebijing administration plus conventional
therapy; C: volunteers; M means male; F means female.
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Chase Sun Pharmaceutical Co., Ltd., Tianjin, China)
was added to the regimen; 100 mL of 1 : 1 (vol : vol)
Xuebijing in saline was administered intravenously ev-
ery 12 h for 14 days.
Blood samples were drawn from patients in Group A
and Group B upon admission to the hospital and prior
to treatment (day 0), then at days 5, 10, and 14 after
admission. Serum was obtained by centrifugal separa-
tion. A single blood (serum) sample was obtained from
each of the Group C participants upon enrollment in-
to the study and prepared for use as controls. All sam-
ples were stored at -20°C until analysis. The concentra-
tions of serum TGF-β1 and PIIIP were determined by
enzyme-linked immunosorbent assay (ELISA) kits, ac-
cording to the manufacturer's instructions (Adlitteram
Diagnostic Laboratories, San Diego, CA, USA). Pa-
tients in Group A and Group B were followed for 1
month, and mortality rates were compared between
the two groups.
Statistical analysis
Quantitative data are expressed as the mean± standard
deviation (SD). Inter- and intra-group differences were
analyzed by one-way analysis of variance (ANOVA)
and the Newman-Keuls test. Differences between the
groups were expressed as percentages, and statistical sig-
nificance was determined by Fisher's exact test. All
analyses were conducted using the SPSS statistical soft-
ware package (v13.0; SPSS, Chicago, IL, USA). A
P-value of <0.05 was considered statistically significant.
RESULTS
Survival among group A and group B
By day 5 after treatment, two of the 19 patients in
Group A died, and two of the 17 patients in Group B
died. By day 10, one additional patient died in Group
A (bringing the total deaths to three), but no addition-
al patients died in Group B (two deaths). By day 14,
eight additional patients of the 19 patients in Group A
died. The overall 2-week survival rate of Group A was
42.1% (8/19). However, by day 14, only four addition-
al patients died in Group B. The overall 2-week surviv-
al rate of Group B was 64.7% (11/17).
Increased serum TGF-β1 and PIIIP levels in response
to PQ poisoning decreased by intravenous Xuebijing
therapy
The concentrations of serum TGF-β1 and PIIIP were
significantly higher in PQ poisoning patients com-
pared with those of the control subjects, as measured
in Group A and Group B at day 0 (immediately upon
admission with PQ poisoning) and compared with
that of Group C (both P<0.01). Moreover, as the
PQ-induced disease progressed over the 2-week obser-
vation period, serum levels of TGF-β1 and PIIIP persis-
tently increased. TGF-β1 increased nearly sevenfold in
Group A (104.7±13.7 at admission to 707.5±14.2 by
day 14) and more than fivefold in Group B (112.2 ±
14.3 at admission to 589.7±12.4 by day 14). However,
the change in TGF-β1 expression in Group B was sig-
nificantly less compared with that of Group A (P<0.01),
indicating that the Xuebijing treatment dampened this
cytokine response. Likewise, PIIIP expression increased
in Group A by approximately fourfold (13.6 ±3.7 at ad-
mission to 48.8± 3.4 by day 14) and in Group B by
threefold (12.3±1.9 at admission to 36.9±3.5 by day
14). The change in PIIIP levels over the 2-week period
was significantly less in Group B compared with that of
Group A (P<0.01), indicating that the intravenous Xue-
bijing therapy also dampened the PIIIP cytokine re-
sponse.The data are summarized inTable 2.
Mortality rates at 1 month after PQ poisoning
At 1 month after PQ poisoning and the initiation of
the treatment regimens, 84.2% of the patients in
Group A (16/19) died, whereas only 47.1% of patients
in Group B (8/17) died. The difference between mor-
tality rates was significant (P=0.0328<0.05, Fisher's ex-
act test; Table 3), indicating that the therapy of conven-
tional treatment plus Xuebijing treatment increased
the 1-month survival rate.
DISCUSSION
PQ (1,1′-dimethyl-4,4′-bipyridinium dichloride) is a
broad-spectrum, non-selective contact herbicide.
Worldwide, PQ has been used widely in agriculture
Table 2 Concentrations of serumTGF-β1 and PIIIP ( xˉ ±s)
Group
A
day 0
day 5 after
admission
day 10 after
admission
day 14 after
admission
B
day 0
day 5 after
admission
day 10 after
admission
day 14 after
admission
C
n
19
17
16
8
17
15
15
11
20
TGF-β1, pmol/L
104.7±13.7a
367.2±18.7ba
503.7±14.3bca
707.5±14.2bcda
112.2±14.3ae
285.3±11.7baf
412.5±16.8bcaf
589.7±12.4bcdaf
87.2±12.6
PIIIP, ng/mL
13.6±3.7a
20.4±3.1ba
36.7±2.6bca
48.8±3.4bcda
12.3±1.9ae
16.7±2.2baf
27.3±3.4bcaf
36.9±3.5bcdaf
7.2±2.1
Notes: A: patients treated with conventional therapy; B: patients
treated with intravenous Xuebijing administration plus
conventional therapy; C: volunteers; statistical significance
within each group: bP<0.01 vs day 0; cP<0.01 vs day 5 after
admission; dP<0.01 vs day 10 after admission. Statistical
significance between each group: aP<0.01 vs Group C; fP<0.01
vs Group A; eP>0.05 vs Group A.
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since the 1960s and has a good occupational safety re-
cord compared with other widely used herbicides.8
However, the high toxicity of PQ associated with
long-term direct dermal exposure and short-term oral
ingestion have led to its being banned from use in Eu-
ropean Union countries and it is used, unfortunately,
as a suicidal agent in many developing nations. Inten-
tional oral ingestion of even small amounts of PQ
causes severe and irreversible systemic damage that is re-
fractory to any known treatment.1, 9 To date, no chelat-
ing agent has been discovered or developed that is capa-
ble of binding PQ in the blood or other tissues; there-
fore, the lethal toxicity of PQ continues to produce
mortality rates of 60%-80% .10, 11 The EU ban of PQ
was established to prevent death by accidental inges-
tion.12 In China, however, PQ is still widely in use
throughout the vast rural regions, because of its herbi-
cidal effectiveness, inexpensiveness, and ease of accessi-
bility.13 Since 1984, when PQ was first officially ap-
proved by the Chinese government for import, PQ has
also arisen as a significant suicide agent. It has been re-
ported that up to 99% of the PQ poisoning cases in
China are intentional ingestion for the purposes of sui-
cide, and the mortality rate is greater than 90%.12
Upon ingestion, PQ rapidly distributes to most of the
organs in the body, but the highest concentrations are
found in the kidneys and lungs. PQ accumulation in
the lung is facilitated by type I and II alveolar epithelial
cells via the polyamine uptake pathway.6 Subsequent re-
dox cycling and free radical generation initiate a neutro-
phil-mediated inflammatory response in the lungs,
which in turn initiates an irreversible fibrotic process
that leads to complete asphyxiation within several
weeks.14 A large oral dose of PQ (>30 mg/kg in hu-
mans) rapidly leads to death from multi-organ failure
that includes lung pathological findings indicating dis-
rupted alveolar epithelial cells, hemorrhage, edema,
and infiltration of inflammatory cells into the intersti-
tial and alveolar spaces. Smaller doses of PQ (from
16 mg/kg) may also lead to death, but the process is
slower, occurs over several days to weeks, and involves
a progressive lung fibrosis consisting of proliferation of
fibroblasts and excessive collagen deposition.10 This pro-
tracted pathogenesis indicates that the main target or-
gan for PQ toxicity is the lung. The pulmonary lesions
that arise during PQ pathogenesis have been attributed
to the formation of oxygen-derived free radicals and lip-
id peroxidation products, whereas activation of "resi-
dent" macrophages are implicated in the concomitant
lung fibrosis.15
Many treatments have been developed for PQ poison-
ing based upon our current understanding of the mech-
anism of PQ pathogenesis, but none have proved cura-
tive.1 Hemoperfusion, combined hemodialysis-hemo-
perfusion, and continuous arteriovenous hemofiltra-
tion aim to enhance the systemic elimination of PQ.9
Polyamines and D-propranolol are administered to pre-
vent the uptake of PQ into the lungs, whereas cyclo-
phosphamide and PQ-specific antibodies are believed
to increase the efflux of PQ from the lungs. To prevent
the redox cycling or to reduce its consequences, forced
inspiratory oxygen is restricted, and patients are given
vitamin E, superoxide dismutase, ascorbic acid, desfer-
rioxamine, selenium, niacin, or N-acetylcysteine. Final-
ly, in an attempt to reduce the fibrous reaction, cortico-
steroids, immunosuppressive agents, fibrinolytic agents,
colchicine, and radiotherapy can be applied. Unfortu-
nately, even when combined, the efficacy of these thera-
peutic methods is poor.1, 9, 11
Transforming growth factor-β (TGF-β), a multifunc-
tional cytokine, is present in mammals as three iso-
forms. Although TGF-βs have been shown to regulate
numerous biological processes in vitro and are ubiqui-
tously expressed in vivo, the TGF-β1 isoform is most
prominently associated with fibrosis-related diseases.16
TGF-β1 was first purified from human platelets, placen-
tas, and bovine kidneys, and was designated as a trans-
forming growth factor based upon its ability to induce
a transformed phenotype in mesenchymal cells. Since
then, TGF-β1 has been identified and functionally char-
acterized in nearly all human cells, especially in lung
macrophages, epithelial cells, and fibroblasts.17 TGF-β1
is believed to be a critical mediator of pathologic, fi-
brotic, and remodeling responses in the lung and other
organs, and these responses are believed to be mediated
by TGF-β1 to activate fibrogenic and apoptotic "inju-
ry" pathways.18 Based on the known effects of TGF-β1
on connective tissue synthesis, the presence of TGF-β1
in the alveolar space is likely to result in the recruit-
ment of inflammatory cells, intra-alveolar inflamma-
tion, and fibroblast proliferation, as well as increased
connective tissue synthesis by fibroblasts.19 Moreover,
this hypothesis is supported by the facts that TGF-β1
levels are increased in the lungs of animal models of
pulmonary fibrosis and that the peptide is present at
sites of extracellular matrix deposition in patients with
cryptogenic fibrosing alveolitis.16, 17
PIIIP, an elongated molecule with a molecular mass of
42 kDa that consists of three identical polypeptide
chains linked by disulfide bonds, is synthesized by fi-
broblasts as a precursor of collagen type III.20, 21 PIIIP is
a crucial component of type III collagen synthesis and
appears to be the major collagenous factor in fibrosis.20
In previous studies of sarcoidosis patients, it was found
that PIIIP concentrations in the lavage fluid were relat-
Table 3 Mortality rates of patients at 1 month after poison-
ing and initiation of conventional or intravenous Xuebi-
jing-supplemented treatments
Notes: A: patients treated with conventional therapy; B: patients
treated with intravenous Xuebijing administration plus conven-
tional therapy; P=0.0328<0.05 by Fisher's exact test.
Group
A
B
Death
16
8
Survival
3
9
Total
19
17
Mortality rate (%)
84.2
47.1
587
JTCM |www. journaltcm. com December 15, 2012 |volume 32 | Issue 4 |
Zheng XB et al. Intravenous Xuebijing on TGF β1 and PIIIP in acute PQ poisoning
ed to lung volume, diffusion capacity, and radiographic
stage, providing indirect support for PIIIP's potential
as a marker of the pulmonary fibrotic process.21 The se-
rum level of PIIIP has also been proposed as a marker
for fibrogenesis. In recent years, studies have indicated
that an increase in serum PIIIP over a prolonged peri-
od of time reflects the development of tissue fibrosis be-
cause PIIIP increases along with collagen synthesis.20
Thus, increases in PIIIP concentrations may be an ear-
ly indication of type III collagen metabolism and of
pre-fibrotic pathology.22 Clinical assessment of serum
PIIIP expression could, therefore, be important in the
early detection of pulmonary fibrosis.23
The effect of TGF-β1 and PIIIP in the pathogenesis of
PQ-induced pulmonary fibrosis was evaluated in this
study, especially as it relates to the curative effect of a
traditional Chinese medicine, the parenteral Xuebijing
solution. The serum TGF-β1 and PIIIP concentrations
of patients who suffered PQ poisoning were found to
be noticeably increased at the early period of the dis-
ease and exhibited a gradually increasing trend as the
pathological process progressed. These results indicated
that TGF-β1 and PIIIP played an important role in the
pathogenesis of PQ-induced pulmonary fibrosis. The
synthesis and secretion of TGF-β1 and PIIIP might
have been induced by the uptake of PQ and/or its ac-
cumulation in the lung. Once present at persistently
high levels, TGF-β1 and PIIIP may exert robust fibrot-
ic effects and induce the excessive pulmonary fibrosis
that is observed in PQ-poisoned patients. The fact
that intravenous Xuebijing therapy with conventional
treatment significantly reduced cytokine concentra-
tions suggested that the development of pulmonary fi-
brosis induced by PQ poisoning could be inhibited by
the Xuebijing solution. Xuebijing treatment becomes
more promising as an anti-PQ-poisoning agent when
considering that the survival rate of PQ-poisoned pa-
tients treated with Xuebijing was significantly better.
The Xuebijing solution that is clinically administered
is an intravenous preparation composed of 32 tradition-
al Chinese medicines. The principal components are
Flos carthami, Radix Paeoniae Rubra, Rhizoma Ch-
uanxiong, Radix Salviae miltiorrhizae, Radix Angelica
sinensis, and Herba houttuyniae.24 Intravenous Xuebi-
jing therapy is widely used throughout China and has
shown clinical success in the treatment of systemic in-
flammatory response syndrome (SIRS) and multiple or-
gan dysfunction syndrome (MODS).25 The active in-
gredients of the preparation were recently determined
by mass spectrophotometry and included safflor yellow
A, ligustrazine, tanshinol, ferulaic acid, and peoniflo-
rin.26 Ferulaic acid has been previously described for its
ability to eliminate oxygen free radicals (OFR) and pre-
vent pulmonary fibrosis.26 Ligustrazine can also elimi-
nate OFR and has been shown to prevent ischemia-re-
perfusion injury, acute respiratory distress syndrome
(ARDS), and acute lung injury (ALI) by this mecha-
nism. Tanshinol acts to inhibit anoxic vasoconstriction,
thus preventing ARDS.26, 27 It has been demonstrated
that intravenous Xuebijing therapy is highly effective
against endotoxin-induced tissue damage and has
shown inhibitory actions on uncontrolled endogenous
mediators of inflammation that are released from endo-
toxin-stimulated mononuclear macrophages.27 In addi-
tion, intravenous Xuebijing therapy has been shown to
inhibit the expression of procollagen mRNA, decrease
the content of lipid peroxidation, increase the activity
of superoxide dismutase, reduce the generation of fibro-
blasts, and inhibit the sedimentation of extracellular
matrix (thereby reducing the expression of TGF-β1).27, 28
All of these functions are related to the development of
pulmonary fibrosis and provide insights into the pre-
cise mechanism by which intravenous Xuebijing thera-
py might protect patients against PQ-induced asphyxia-
tion and death.28
In conclusion, serum concentrations of TGF-β1 and
PIIIP were significantly lower in Group A compared
with those of Group B. Moreover, the mortality rate in
Group B was clearly lower than that of Group A.
These results imply that intravenous Xuebijing therapy
might function to down-regulate TGF-β1 and PIIIP,
thus suppressing PQ-induced pulmonary fibrosis.
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